CLINICAL AND PHARMACOKINETIC RESULTS AFTER THE SWITCH TO INFLIXIMAB BIOSIMILAR IN INFLAMMATORY BOWEL DISEASE: 2 YEARS OF REAL-LIFE EXPERIENCE (submitted in 2019)
CLINICAL AND PHARMACOKINETIC RESULTS AFTER THE SWITCH TO INFLIXIMAB BIOSIMILAR IN INFLAMMATORY BOWEL DISEASE: 2 YEARS OF REAL-LIFE EXPERIENCE (submitted in 2019)